Nykode Therapeutics AS Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2022
2021
2020
2019
7M
-78.89%
0M
0M
61M
9M
27M
-54M
0M
-51M
-8M
-43M
354.04%
42M
3M
-49M
2M
-53M
34M
-84.20%
0M
0M
45M
9M
16M
-11M
0M
-11M
-2M
-9M
-106.29%
28M
0M
-10M
1M
-11M
215M
387,669.85%
0M
0M
37M
9M
11M
178M
0M
181M
31M
150M
-1,476.60%
21M
0M
181M
0M
178M
0M
-
0M
0M
11M
0M
0M
-11M
0M
-11M
0M
-11M
-1,476.60%
9M
0M
-11M
0M
-14M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3M
325.93%
0M
0M
17M
0M
0M
-14M
2M
-12M
-2M
-10M
-31.20%
0M
2M
0M
1M
0M
5M
60.57%
0M
0M
17M
0M
14M
-12M
1M
-10M
-1M
-9M
5.28%
11M
2M
-9M
1M
-12M
3M
337.20%
0M
0M
20M
0M
13M
-17M
1M
-12M
-2M
-10M
50.20%
11M
3M
-11M
0M
0M
3M
-91.30%
0M
0M
17M
0M
23M
-15M
6M
-12M
0M
-12M
-213.34%
9M
3M
-18M
0M
-14M
1M
-
0M
0M
21M
0M
2M
-20M
2M
-19M
-4M
-15M
-213.34%
15M
1M
-16M
0M
-20M
3M
-
0M
0M
13M
0M
10M
-10M
2M
-11M
-2M
-9M
-213.34%
0M
-1M
-8M
0M
0M
1M
-
0M
0M
9M
0M
7M
-9M
1M
-9M
-2M
-7M
-213.34%
0M
0M
-8M
0M
0M
31M
-
0M
0M
16M
0M
5M
15M
2M
15M
5M
11M
-213.34%
0M
1M
13M
0M
0M